Ezetimibe/rosuvastatin
Ezetimibe (top) and rosuvastatin (bottom)
Combination of
EzetimibeHypolipidemic agent
RosuvastatinStatin
Clinical data
Trade namesRidutrin,Cholerose Plus, Lipocomb, Rosuzet, others[1][2]
AHFS/Drugs.comMultum Consumer Information
License data
Pregnancy
category
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol.[6][7] In some countries it is sold as a kit or a pack containing two distinct pills.[8][1]

The combination was approved for medical use in the United States in March 2021.[5]

Medical uses

Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.[9]

Pharmacology

Ezetimibe/rosuvastatin combines two lipid-lowering therapies with distinct actions to achieve greater lowering of LDL-C that either agent alone.

Together, these drugs cause a net decrease in hepatocyte intracellular cholesterol leading to scavenging of LDL particles from the blood via upregulation of the LDL receptor.

References

  1. 1 2 "Rosuvastatin international". Drugs.com. 3 February 2020. Retrieved 17 February 2020.
  2. 1 2 "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
  3. 1 2 "TGA eBS - Product and Consumer Medicine Information Licence".
  4. "EZESTAT COMPOSITE PACK (Pharmacor Pty Ltd)". Department of Health and Aged Care. Archived from the original on 18 March 2023.
  5. 1 2 "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
  6. "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Retrieved 17 February 2020.
  7. Willihnganz MJ, Gurevitz SL, Clayton BD (November 2021). "HMG-CoA Reductase Inhibitor Combination Products". Clayton's Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. p. 344. ISBN 978-0-323-81258-0.
  8. "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Retrieved 17 February 2020.
  9. Sharretts J (23 March 2021). "NDA Approval Letter for Roszet (rosuvastatin and ezetimibe)" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
  10. 1 2 "DailyMed - ROSZET- rosuvastatin and ezetimibe tablet ROSZET (- rosuvastatin and ezetimibe tablet". dailymed.nlm.nih.gov. Retrieved 14 January 2024.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.